HALLE/SAALE, Germany, July 8, 2013 – Probiodrug AG (Probiodrug) announced that it will be making two poster and two oral presentations at the upcoming Alzheimer’s Association International Conference in Boston, MA July 13 – 18, 2013. These presentations will provide further insight into the rationale of targeting QC for the treatment of Alzheimer’s disease. In addition, it will be presenting collaborative data on the efficacy and safety in animal models of a passive immunotherapy against Pyroglutamate-3 Abeta. Moreover, these presentations will provide results from first human studies with PQ912, a small molecule QC-inhibitor, in healthy elderly.
“The annual AAIC meeting is the world’s largest gathering of Alzheimer’s, dementia and neuroscience specialists, making it an important forum for the discussion of novel approaches such as ours to the treatment of AD,” said Dr. Konrad Glund, CEO of Probiodrug. “We believe that QC inhibition has significant potential to slow the progression of AD and may even be able to reverse some of the cognitive deficits associated with the disease. PQ912, our experimental QC inhibitor, is currently in late Phase 1 clinical studies, and we look forward to testing this hypothesis as we advance the candidate through patient studies.”
Sunday, July 14, 11:45am – 2:15pm: Safety, Pharmacokinetics and Pharmacodynamics of PQ912, the first Glutaminyl Cyclase (QC) Inhibitor to Treat AD, in Healthy Elderly Subjects. Poster Session; Program Code: P1.
Sunday, July 14, 4:00-5:30pm: pGlu-Abeta peptides, highly abundant in AD brain, are cytotoxic in vitro, in situ and in vivo. Oral Session – Therapeutics; Program Code: O1-11.
Monday, July 15, 11:45am – 2:15pm: Passive Immunization against Pyroglutamate-3 Abeta Decreases Total Plaque Load in the Absence of Microhemorrhage and Attenuates Cognitive Deficits in APP/PS1dE9 Mice. Poster Session; Program Code: P2.
Monday, July 15, 4:00-5:30pm: Characterization of double transgenic mice, APPSLxhQC, exhibiting enhanced pyroGlu3-Abeta formation to evaluate efficacy of Glutaminyl Cyclase (QC) inhibitors. Oral Session – Basic Translational Science; Program Code: O2-07.
More information on the conference and sessions may be found on the AAIC website here: www.alz.org/aaic.
PQ912 is a small molecule that targets glutaminyl cyclase (QC), an enzyme that catalyzes the formation of pyroglutamated Abeta, thus preventing the formation of highly toxic Abeta species including soluble oligomers. To date, 182 subjects have been enrolled in single- and multiple-dose phase 1 studies of PQ912, and the compound has been found to be safe and well-tolerated across a wide range of doses tested. PQ912 has been shown to inhibit QC activity in the cerebrospinal fluid of healthy subjects in a dose-dependent fashion.
About Probiodrug AG
Probiodrug is a biopharmaceutical company dedicated to the development of therapeutics to treat Alzheimer’s disease. Probiodrug’s core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes which play a central role in the maturation of hormones. Founded in 1997 by Prof. Dr. Hans-Ulrich Demuth and Dr. Konrad Glund, the Company has medical use and composition of matter patents related to the inhibition of glutaminyl cyclase, providing the Company with a dominant position in this field of research and drug development. Probiodrug is backed by institutions such as BB Biotech, Edmond de Rothschild Investment Partners, Goodvent/IBG, HBM, TVM Capital, Life Sciences Partners, Biogen Idec New Ventures, CFH Group, funds managed by Wellington Management and private investors. For more information, please visit https://www.vivoryon.com.
Dr. Konrad Glund, CEO
Tel: +49 (345) 5559900